share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  04/25 16:38
Moomoo AI 已提取核心信息
ZyVersa Therapeutics, Inc., a biopharmaceutical company, has announced the completion of a 1-for-10 reverse stock split of its common stock, effective April 25, 2024. The reverse stock split was previously approved by the company's stockholders during a Special Meeting held on April 17, 2024, where they granted the board of directors the authority to determine the exact split ratio and timing. The board of directors subsequently approved the reverse stock split at the 1-for-10 ratio. Following the split, the common stock began trading on The Nasdaq Capital Market on a split-adjusted basis from market open on April 26, 2024. The par value and other terms of the common stock remain unchanged. The company's post-split common stock CUSIP number is 98987D 300. The amendment to the company's Second Amended and Restated Certificate of Incorporation, detailing the reverse stock split, was filed with the Secretary of State of Delaware and is included as Exhibit 3.1 in the current report.
ZyVersa Therapeutics, Inc., a biopharmaceutical company, has announced the completion of a 1-for-10 reverse stock split of its common stock, effective April 25, 2024. The reverse stock split was previously approved by the company's stockholders during a Special Meeting held on April 17, 2024, where they granted the board of directors the authority to determine the exact split ratio and timing. The board of directors subsequently approved the reverse stock split at the 1-for-10 ratio. Following the split, the common stock began trading on The Nasdaq Capital Market on a split-adjusted basis from market open on April 26, 2024. The par value and other terms of the common stock remain unchanged. The company's post-split common stock CUSIP number is 98987D 300. The amendment to the company's Second Amended and Restated Certificate of Incorporation, detailing the reverse stock split, was filed with the Secretary of State of Delaware and is included as Exhibit 3.1 in the current report.
生物制药公司ZyVersa Therapeutics, Inc. 宣布完成其普通股的1比10反向拆分，自2024年4月25日起生效。反向股票拆分此前已在2024年4月17日举行的特别会议上获得公司股东的批准，他们在会上授权董事会确定确切的分拆比率和时间。董事会随后批准了按1比10的比例进行反向股票拆分。拆分后，普通股从2024年4月26日开盘开始在纳斯达克资本市场进行拆分调整后交易。普通股的面值和其他条款保持不变。该公司拆分后的普通股CUSIP号码为98987D 300。该公司第二次修订和重述的公司注册证书修正案详细说明了反向股票拆分，已提交给特拉华州国务卿，并作为附录3.1包含在本报告中。
生物制药公司ZyVersa Therapeutics, Inc. 宣布完成其普通股的1比10反向拆分，自2024年4月25日起生效。反向股票拆分此前已在2024年4月17日举行的特别会议上获得公司股东的批准，他们在会上授权董事会确定确切的分拆比率和时间。董事会随后批准了按1比10的比例进行反向股票拆分。拆分后，普通股从2024年4月26日开盘开始在纳斯达克资本市场进行拆分调整后交易。普通股的面值和其他条款保持不变。该公司拆分后的普通股CUSIP号码为98987D 300。该公司第二次修订和重述的公司注册证书修正案详细说明了反向股票拆分，已提交给特拉华州国务卿，并作为附录3.1包含在本报告中。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息